Diagnostics

DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies

Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion...

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Custom Health to Close the Market at the TSX on October 22, 2026, and Announces Appointments of Chief Commercial and Strategy Officer and Chief Compliance and Regulatory Officer

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpretation to generate clearer mechanistic...

EY Pulse of the MedTech Industry Report 2026: Blockbuster performers and innovation drive record MedTech industry growth

Broader MedTech industry at turning point, seeking positioning to optimize portfolios, differentiate technology and improve R&DInnovation drives increased dealmaking and...

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis)...

Pillar Biosciences and Collaborators to Present NGS Data Across Solid Tumors, Liquid Biopsy, and Heme Malignancies at 2026 Association for Molecular Pathology (AMP) Annual Meeting

NATICK, Mass., Oct. 15, 2026 /PRNewswire/ -- Pillar Biosciences today announced that ten scientific posters featuring their NGS technology will...

Valion Bio’s Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone

Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive...

error: Content is protected !!